RecruitingNCT06465810

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Studying Amyloidosis

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Treatment of transthyretin (ATTR) amyloidosis in observational study setting(drug)
Enrollment: 1850 enrolled
Eligibility: 18-130 years · All sexes
Timeline: 2024 – 2031

Study locations (30)

Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Washington D.C., District of Columbia, United States
Research Site, Chicago, Illinois, United States
Research Site, Indianapolis, Indiana, United States
Research Site, Boston, Massachusetts, United States
Research Site, Rochester, Minnesota, United States
Research Site, Kansas City, Missouri, United States
Research Site, St Louis, Missouri, United States
Research Site, New Brunswick, New Jersey, United States
Research Site, Manhasset, New York, United States
Research Site, New York, New York, United States
Research Site, Durham, North Carolina, United States
+15 more locations on ClinicalTrials.gov

Collaborators

ICON plc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06465810 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis →

← Back to all trials